In an effort to diversify its revenue base beyond the multiple sclerosis therapy Ampyra® (dalfampridine), Acorda Therapeutics has agreed to acquire Finland-based Biotie Therapies in an all-cash deal valued at approximately US$363 M. The combined company will have three clinical-stage Parkinson’s disease (PD) candidates in its development pipeline, including the Phase III adenosine A2A receptor antagonist tozadenant and SYN120, which is being evaluated in a Phase IIa trial for PD-related dementia.